InsiderTrades.com logo
Jason P. Rhodes net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jason Rhodes Biography and Net Worth

Director of Dyne Therapeutics

Jason is a partner with Atlas Venture, where he focuses on creating and building novel therapeutics companies. He is a founder and the chairman of Dyne, Generation Bio (NASDAQ: GBIO), Rectify Pharmaceuticals, and Disarm Therapeutics (acquired by Lilly). He was also previously on the board of Replimune (NASDAQ: REPL).

Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

What is Jason P. Rhodes' net worth?

The estimated net worth of Jason P. Rhodes is at least $138.77 thousand as of May 5th, 2026. Mr. Rhodes owns 8,390 shares of Dyne Therapeutics stock worth more than $138,771 as of May 18th. This net worth approximation does not reflect any other assets that Mr. Rhodes may own. Learn More about Jason P. Rhodes' net worth.

How do I contact Jason P. Rhodes?

The corporate mailing address for Mr. Rhodes and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on Jason P. Rhodes' contact information.

Has Jason P. Rhodes been buying or selling shares of Dyne Therapeutics?

In the last ninety days, Jason P. Rhodes has sold $29,694,469.45 in shares of Dyne Therapeutics stock. Most recently, Jason P. Rhodes sold 83,219 shares of the business's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $18.18, for a transaction totalling $1,512,921.42. Following the completion of the sale, the director now directly owns 7,962 shares of the company's stock, valued at $144,749.16. Learn More on Jason P. Rhodes' trading history.

Who are Dyne Therapeutics' active insiders?

Dyne Therapeutics' insider roster includes Oxana Beskrovnaya (Chief Scientific Officer), Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Johanna Friedl-Naderer (Chief Commercial Officer), Susanna High (COO), Carlo Incerti (Director), Dirk Kersten (Director), Jason Rhodes (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.

Are insiders buying or selling shares of Dyne Therapeutics?

During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 103,000 shares worth more than $956,180.00. During the last year, insiders at the sold shares 15 times. They sold a total of 1,562,102 shares worth more than $29,850,148.21. The most recent insider tranaction occured on May, 13th when insider Johanna Friedl-Naderer sold 228 shares worth more than $4,186.08. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.

Information on this page was last updated on 5/13/2026.

Jason P. Rhodes Insider Trading History at Dyne Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/6/2026Sell83,219$18.18$1,512,921.427,962View SEC Filing Icon  
5/5/2026Sell11,600$18.03$209,148.008,390View SEC Filing Icon  
5/4/2026Sell11,904$18.00$214,272.008,450View SEC Filing Icon  
4/28/2026Sell227,337$18.38$4,178,454.068,511View SEC Filing Icon  
4/27/2026Sell173,493$18.15$3,148,897.959,682View SEC Filing Icon  
4/24/2026Sell137,948$18.48$2,549,279.0410,576View SEC Filing Icon  
4/23/2026Sell73,108$19.19$1,402,942.5211,286View SEC Filing Icon  
4/22/2026Sell287,956$19.68$5,666,974.0811,663View SEC Filing Icon  
4/21/2026Sell274,297$19.52$5,354,277.4413,148View SEC Filing Icon  
4/20/2026Sell272,049$20.06$5,457,302.9414,561View SEC Filing Icon  
11/14/2024Sell782$33.10$25,884.2015,962View SEC Filing Icon  
2/28/2024Sell190,920$24.84$4,742,452.80864,487View SEC Filing Icon  
2/26/2024Sell248,219$23.72$5,887,754.68903,527View SEC Filing Icon  
2/22/2024Sell119,360$22.66$2,704,697.606,512,104View SEC Filing Icon  
2/20/2024Sell169,539$22.72$3,851,926.086,815,965View SEC Filing Icon  
2/15/2024Sell177,906$23.89$4,250,174.347,148,211View SEC Filing Icon  
12/12/2022Buy934,581$10.70$10,000,016.70934,581View SEC Filing Icon  
See Full Table

Jason P. Rhodes Buying and Selling Activity at Dyne Therapeutics

This chart shows Jason P Rhodes's buying and selling at Dyne Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dyne Therapeutics Company Overview

Dyne Therapeutics logo
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $16.54
Low: $16.40
High: $17.46

50 Day Range

MA: $18.36
Low: $14.86
High: $20.41

2 Week Range

Now: $16.54
Low: $8.06
High: $25.00

Volume

1,584,899 shs

Average Volume

1,485,807 shs

Market Capitalization

$2.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08